Tag Archive | "Forest"

Partnering Agreements with Forest

Tags: , , , , , , ,


This report provides all the information you require to better understand Forest and its partnering interests and activities over the past seven years. Read the full story

Big pharma company Forest joins forces with Nabriva in anti-bacterial co-development pact

Tags: , , ,


Forest Laboratories, a big pharma company is paying Nabriva Therapeutics $25 million in a co-development deal for Nabriva’s antibacterial agent, BC-3781, and the right to acquire Nabriva over the next 12 months Read the full story

Forest: Company Profile

Tags: ,


Forest Laboratories, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Forest Laboratories inks pharma alliances agreement with Janssen Pharmaceutica for Bystolic

Tags: , , , ,


Forest Laboratories announced that Forest Laboratories and Janssen Pharmaceutica entered into a pharma alliances agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension, thereby eliminating all future royalties. Read the full story

AstraZeneca tipped to buy US group Forest as it loses Seroquel patent case

Tags: , , ,


AstraZeneca could be on the acquisition trail, analysts believe, with US group Forest Laboratories tipped as a prime target. Read the full story

Forest looking at earlier assets for drug pipeline, next decade of business

Tags: , ,


With its battle for board control with billionaire Carl Icahn over (at least for this year), Forest Laboratories has its eyes on ensuring that its pipeline of experimental meds positions it for success, company CFO Frank Perier told ReutersRead the full story

Current Agreements Deals Update – March 2011

Tags: , , , , , , , , , , , , , , , ,


Review of deals and alliances during February 2011. Read the full story

Forest swallows Clinical Data in $1.2 billion buyout

Tags: , ,


Only weeks after Clinical Data obtained approval for a new antidepressant Read the full story

Forest to acquire Clinical Data, Inc. in $1.2bn buyout

Tags: ,


Forest Laboratories, Inc. and Clinical Data, Inc. have announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd™ Read the full story

Forest and Gruenenthal announce Forest’s acquisition of Gruenenthal’s cystic fibrosis franchise in Europe

Tags: ,


Forest Healthcare B.V. and Gruenenthal GmbH have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe. Colistin is an antibiotic used to treat the principal bacterial infections in cystic fibrosis patients, and Colobreathe is a novel dry powder inhaler containing colistin developed by Forest and currently being reviewed by the European Medicines Agency Read the full story